BMSON Header
보건의료전문가가 아닌 경우, 한국BMS Official Site (https://www.bms.com/kr)을 방문해 주세요.

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

Oct 26, 2021

Error
Error
Success
Success